

Sheppard Mullin Represents Anpac Bio-Medical, Genprex, Majesco and Others in Recent Deals

02.19.2020

- Represented **Ameri Holdings, Inc.** (NASDAQ: AMRH) (“Ameri”) as the issuer in its amalgamation agreement with Jay Pharma Inc., a Canadian company dedicated to developing innovative, evidence-based cannabinoid products and combination therapies to address unmet needs in cancer care. In connection with the Amalgamation, Ameri will spin-off its existing IT services business to a private entity founded by Ameri management in partnership with Ameri’s current Series A Preferred Equity Holders. The transactions are expected to close in the first half of 2020. The Sheppard Mullin deal team was led by partner Richard Friedman and included partner John Hempill and associate Justin Anslow. Special assistance was provided by partners Eric Altman, Dmitriy Chelnitsky, Judith Fiorini, and Daniel Schnapp, special counsel Sean Kirby and associate Alana Berrocal. (January 13)
- Represented **Alan King and Company**, a leading software company in the mortgage industry that specialized in master servicing and loan accounting software solutions, in its acquisition by SitusAMC Holdings Corp., the leading provider of services and technology solutions to the real estate finance industry. Terms of the deal were not disclosed. The Sheppard Mullin team, led by partner Josh Dean, included partner Carlo Van den Bosch and associates Linda Igarashi, Allen Babajanian, and John Crisp. (January 21)
- Advised **Genprex, Inc.**, a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, in connection with a \$8.0 million registered direct offering of common stock. Genprex’s common stock is listed on the Nasdaq Capital Market under the symbol “GNPX.” The Sheppard Mullin team, led by partner Richard Friedman, included partner Stephen Cohen and associates Nazia Khan, Alexander Yarbrough, and Matthew Hayes (January 27)
- Represented **Histogen**, a privately-held regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, in a reverse merger with Conatus Pharmaceuticals, a biotechnology company that has been focused on the development of novel medicines to treat chronic diseases with significant unmet need. The Sheppard Mullin team, led by partner Will Chuchawat, included partner Jeff Fessler and special counsel Andreas Pour. (January 28)
- Represented **Majesco** (NASDAQ: MJCO), a global leader of cloud insurance software solutions for insurance business transformation, in its January 30 acquisition of InsPro Technologies (OTCBB: ITCC), a software leader in the life and annuity insurance market. The Sheppard Mullin deal team was led by New York partner Valérie Demont and included Matthew McCalip, Michael Chan, Dmitriy Chelnitsky, Judith Fiorini, Dan Yannuzzi, Sean Kirby, Brian Egan, Nazia Khan, Trevor Quist, Paris Rebeil, and Matthew Shatzkes. (January 30) [Click here to read the press release.](#)

- Advised the underwriters in connection with a \$16 million initial public offering of American depositary shares (ADSs) of **AnPac Bio-Medical Science Co., Ltd.** AnPac's ADSs began trading on the Nasdaq Global Market on January 30, 2020 under the ticker symbol "ANPC." Anpac Bio is a leading biotechnology company with operations in China and the United States focused on early cancer screening and detection. The Sheppard Mullin deal team was led by partners Richard Friedman and Stephen Cohen, and associates Yuanmei Lu, Nazia Khan, and Matthew Hayes. Partner Jing Liu and associate Paul Chang provided advice on intellectual property matters. Partner Allison Fulton provided advice on FDA matters. (January 30)
- Served as real estate counsel to a **European-based private equity firm** in connection with the \$20 million financing of certain United States cannabis-related real estate assets. The financing, which closed in four weeks, is primarily secured by mortgages on 12 properties located in eight states. Each property is licensed to cultivate, manufacture, and/or retail medical marijuana products. New York partners Ross Honig and Peter Koffler led the Sheppard Mullin team which also included associate Jordan Ehrlich. (January 30)
- Represented **Chicago Entrepreneurial Center (CEC dba 1871)**, Chicago's digital technology hub and the #1 ranked private business incubator in the world, in its acquisition of the Illinois Technology Association (ITA), a nonprofit organization that supports the growing Illinois technology community. The partnership will drive collective acceleration for early-stage, growth-stage, and enterprise companies. The Sheppard Mullin team was led by Chicago office managing partner and Chairman of the Board of the CEC and 1871, Larry Eppley and Chicago special counsel Carrie McNally, and included Chicago attorneys Mike Roth, Kevin Ryan, Shawn Fabian, Nika Palama, Lauren Mioduszewski and Julie Kadish. (February 18)

Attorneys

Eric L. Altman

Christopher J. Bosch

Michael Chan

Paul Chang

Dmitriy Chelnitsky

Stephen A. Cohen

John G. Crisp

Joshua A. Dean

Valérie Demont

Brian C. Egan

Jordan A. Ehrlich

Lawrence C. Eppley

Shawn D. Fabian

Jeffrey J. Fessler

Richard A. Friedman

Allison Fulton

John R. Hempill

Ross A. Honig

Linda Igarashi

Julia K. Kadish

Nazia J. Khan

Sean J. Kirby

Peter G. Koffler

Jing Liu

Yuanmei Lu

Matthew A. McCalip

Carrie C. McNally

Lauren M. Mioduszewski

Nika B. Palama

Trevor J. Quist

Paris Rebeil

Michael J. Roth

Kevin M. Ryan

Daniel E. Schnapp

Matthew M. Shatzkes

Daniel N. Yannuzzi

Practice Areas

Corporate